{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:05Z","timestamp":1777420385866,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>\n                    Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of the fixed-dose combination (FDC) product, QTERN (dapagliflozin\/saxagliptin) tablets. Data Sources: Searches of MEDLINE (1946 to July 1, 2017) were conducted using the keywords QTERN, saxagliptin, and dapagliflozin. Additional data were obtained from the prescribing information, the product dossier, and Clinicaltrials.gov . Study Selection and Data Extraction: All English language articles related to pharmacology, pharmacokinetics, efficacy, or safety of the combination therapy in human subjects were reviewed. Data Synthesis: The pharmacokinetics of saxagliptin and dapagliflozin were not affected significantly when administered as an FDC product. Saxagliptin may suppress the increased secretion of glucagon associated with dapagliflozin. The combination dapagliflozin\/saxagliptin has been studied as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus (T2DM). The difference in hemoglobin A\n                    <jats:sub>1C<\/jats:sub>\n                    (A1C) between saxagliptin + dapagliflozin + metformin (triple therapy) and saxagliptin + metformin was \u22120.59 (95% CI = \u22120.81 to \u22120.37, P &lt; 0.0001), and the difference between triple therapy and dapagliflozin + metformin was \u22120.27 (95% CI = \u22120.48 to \u22120.05, P = 0.0166). The combination was well tolerated when added to metformin. Conclusion: QTERN (dapagliflozin\/saxagliptin) tablets are a reasonable option for patients with T2DM not controlled on metformin, but cost, insurance coverage, and a lackluster reduction in A1C will likely limit its use until more data regarding its effects on complications of diabetes and cardiovascular outcomes become available.\n                  <\/jats:p>","DOI":"10.1177\/1060028017731111","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T05:58:51Z","timestamp":1504850331000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Dapagliflozin\/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes"],"prefix":"10.1177","volume":"52","author":[{"given":"Valerie Azzopardi","family":"Coppenrath","sequence":"first","affiliation":[{"name":"MCPHS University, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasmina","family":"Hydery","sequence":"additional","affiliation":[{"name":"UMass Medical School\u2014Clinical Pharmacy Services (CPS), Shrewsbury, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"bibr2-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S011"},{"key":"bibr3-1060028017731111","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00336"},{"key":"bibr4-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2517"},{"key":"bibr5-1060028017731111","unstructured":"QTERN (dapagliflozin\/saxagliptin) [product information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017."},{"key":"bibr6-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1215427"},{"key":"bibr11-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802710422"},{"key":"bibr12-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009"},{"key":"bibr13-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0029"},{"key":"bibr14-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q538"},{"key":"bibr15-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1253"},{"key":"bibr16-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0030-9"},{"key":"bibr17-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0014-9"},{"key":"bibr18-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"bibr19-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"bibr20-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1142"},{"key":"bibr21-1060028017731111","doi-asserted-by":"publisher","DOI":"10.4158\/EP14489"},{"key":"bibr23-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P003"},{"key":"bibr24-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014540450"},{"key":"bibr25-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0811"},{"key":"bibr26-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0779"},{"key":"bibr27-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/db15-932-1471"},{"key":"bibr28-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2364"},{"key":"bibr29-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"bibr32-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0128-9"},{"key":"bibr33-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1177\/2042018816676239"},{"key":"bibr34-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S012"},{"key":"bibr35-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S013"},{"key":"bibr36-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-S011"},{"key":"bibr37-1060028017731111","doi-asserted-by":"publisher","DOI":"10.2337\/dci15-0036"},{"key":"bibr39-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12937"},{"key":"bibr41-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"bibr42-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"bibr43-1060028017731111","unstructured":"Glyxambi (empagliflozin\/linagliptin) [product information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2017."},{"key":"bibr45-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12015"},{"key":"bibr46-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-014-9938-5"},{"key":"bibr47-1060028017731111","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.570745"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017731111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028017731111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028017731111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:02Z","timestamp":1777374842000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028017731111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1177\/1060028017731111"],"URL":"https:\/\/doi.org\/10.1177\/1060028017731111","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}